title: Nerve growth factor acts through the TrkA receptor to protect sensory neurons from the damaging effects of the HIV-1 viral protein, Vpr.
abstract: Distal sensory polyneuropathy (DSP) with associated neuropathic pain is the most common neurological disorder affecting patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). Viral protein R (Vpr) is a neurotoxic protein encoded by HIV-1 and secreted by infected macrophages. Vpr reduces neuronal viability, increases cytosolic calcium and membrane excitability of cultured dorsal root ganglion (DRG) sensory neurons, and is associated with mechanical allodynia in vivo. A clinical trial with HIV/AIDS patients demonstrated that nerve growth factor (NGF) reduced the severity of DSP-associated neuropathic pain, a problem linked to damage to small diameter, potentially NGF-responsive fibers. Herein, the actions of NGF were investigated in our Vpr model of DSP and we demonstrated that NGF significantly protected sensory neurons from the effects of Vpr. Footpads of immunodeficient Vpr transgenic (vpr/RAG1(-/-)) mice displayed allodynia (p<0.05), diminished epidermalinnervation (p<0.01) and reduced NGF mRNA expression (p<0.001) compared to immunodeficient (wildtype/RAG1(-/-)) littermate control mice. Compartmented cultures confirmed recombinant Vpr exposure to the DRG neuronal perikarya decreased distal neurite extension (p<0.01), whereas NGF exposure at these distal axons protected the DRG neurons from the Vpr-induced effect on their cell bodies. NGF prevented Vpr-induced attenuation of the phosphorylated glycogen synthase-3 axon extension pathway and tropomyosin-related kinase A (TrkA) receptor expression in DRG neurons (p<0.05) and it directly counteracted the cytosolic calcium burst caused by Vpr exposure to DRG neurons (p<0.01). TrkA receptor agonist indicated that NGFacted through the TrkA receptor to block the Vpr-mediated decrease in axon outgrowth in neonatal and adult rat and fetal human DRG neurons (p<0.05). Similarly, inhibiting the lower affinity NGF receptor, p75, blocked Vpr's effect on DRG neurons. Overall, NGF/TrkA signaling or p75 receptor inhibition protects somatic sensory neurons exposed to Vpr, thus laying the groundwork for potential therapeutic options for HIV/AIDS patients suffering from DSP.
authors.affiliation: Division of Anatomy, University of Alberta, Edmonton, Alberta T6G 2H7, Canada. Electronic address: webber2@ualberta.ca.
authors.forename: C A
authors.initials: CA
authors.lastname: Webber
authors.forename: J
authors.initials: J
authors.lastname: Salame
authors.forename: G-L S
authors.initials: GL
authors.lastname: Luu
authors.forename: S
authors.initials: S
authors.lastname: Acharjee
authors.forename: A
authors.initials: A
authors.lastname: Ruangkittisakul
authors.forename: J A
authors.initials: JA
authors.lastname: Martinez
authors.forename: H
authors.initials: H
authors.lastname: Jalali
authors.forename: R
authors.initials: R
authors.lastname: Watts
authors.forename: K
authors.initials: K
authors.lastname: Ballanyi
authors.forename: G F
authors.initials: GF
authors.lastname: Guo
authors.forename: D W
authors.initials: DW
authors.lastname: Zochodne
authors.forename: C
authors.initials: C
authors.lastname: Power
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000818:Animals; D015153:Blotting, Western; D002478:Cells, Cultured; D005333:Fetus; D005455:Fluorescent Antibody Technique; D005727:Ganglia, Spinal; D015658:HIV Infections / Q000150:complications; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D008822:Mice, Transgenic; D020932:Nerve Growth Factor / Q000378:metabolism*; D009437:Neuralgia / Q000378:metabolism / Q000821:virology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D060888:Real-Time Polymerase Chain Reaction; D020917:Receptor, trkA / Q000378:metabolism*; D011984:Sensory Receptor Cells / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology; D054325:vpr Gene Products, Human Immunodeficiency Virus / Q000378:metabolism*
chemical_list: D054325:vpr Gene Products, Human Immunodeficiency Virus; C514912:vpr protein, Human immunodeficiency virus 1; D020932:Nerve Growth Factor; D020917:Receptor, trkA
keywords: 1-β-d-arabinofuranosylcytosine; ACSF; AIDS; ANOVA; AraC; DMEM/F12; DRG; DSP; Dulbecco’s Modified Eagle’s Medium/Ham’s F-12; EDTA; GSK3β; HAART; HIV; NGF; PBS; TrkA; Vpr; acquired immunodeficiency syndrome; analysis of variance; artificial cerebral spinal fluid; distal sensory polyneuropathy; dorsal root ganglion; ethylenediaminetetraacetic acid; glycogen synthase kinase-3 beta; highly active antiretroviral therapy; human immunodeficiency virus; human immunodeficiency virus (HIV); nerve growth factor; nerve growth factor (NGF); neuropathic pain; pGSK3β; phosphate-buffered saline; phosphorylated GSK3β; qRT-PCR; quantitative real-time polymerase chain reaction; tropomyosin-related kinase A; tropomyosin-related kinase A (TrkA); viral protein R; viral protein R (Vpr)
references.citation: J Neurosci. 2010 Jul 7;30(27):9306-15
references.pmid: 20610765
references.citation: Nat Protoc. 2009;4(12):1869-87
references.pmid: 20010935
references.citation: J Biol Chem. 1993 Oct 25;268(30):22838-46
references.pmid: 7693679
references.citation: Arch Neurol. 2004 Apr;61(4):546-51
references.pmid: 15096404
references.citation: Eur J Neurosci. 1998 Apr;10(4):1282-91
references.pmid: 9749782
references.citation: FASEB J. 2010 Nov;24(11):4343-53
references.pmid: 20628092
references.citation: Arch Neurol. 2010 May;67(5):552-8
references.pmid: 20457954
references.citation: Glia. 2011 Oct;59(10):1503-17
references.pmid: 21656855
references.citation: Pain Physician. 2011 Nov-Dec;14(6):E505-24
references.pmid: 22086103
references.citation: Pain. 1983 Dec;17(4):321-339
references.pmid: 6664680
references.citation: Neurology. 2000 Mar 14;54(5):1080-8
references.pmid: 10720278
references.citation: Annu Rev Neurosci. 2001;24:677-736
references.pmid: 11520916
references.citation: J Neurosci. 1994 Mar;14(3 Pt 2):1422-32
references.pmid: 8126547
references.citation: J Neuropathol Exp Neurol. 2008 Mar;67(3):212-22
references.pmid: 18344912
references.citation: Diabetologia. 1992 Sep;35(9):889-97
references.pmid: 1397786
references.citation: Neurosci Lett. 1997 May 30;228(1):33-6
references.pmid: 9197281
references.citation: Can J Neurol Sci. 2009 May;36(3):285-95
references.pmid: 19534327
references.citation: Can J Neurol Sci. 2008 Nov;35(5):551-66
references.pmid: 19235438
references.citation: Brain Res. 2001 May 25;902(1):40-50
references.pmid: 11376593
references.citation: J Neurosci. 2009 Feb 4;29(5):1350-60
references.pmid: 19193882
references.citation: J Neurosci. 2007 Apr 4;27(14):3703-11
references.pmid: 17409234
references.citation: J Neurobiol. 1992 Nov;23(9):1261-76
references.pmid: 1361523
references.citation: J Dermatol Sci. 2000 Feb;22(2):71-9
references.pmid: 10674819
references.citation: J Peripher Nerv Syst. 2001 Mar;6(1):21-7
references.pmid: 11293804
references.citation: J Neurosci. 1992 Apr;12(4):1454-66
references.pmid: 1556603
references.citation: Cell. 1992 Mar 6;68(5):869-77
references.pmid: 1547488
references.citation: Diabetes. 2008 Jun;57(6):1664-73
references.pmid: 18332094
references.citation: Bioessays. 1998 Feb;20(2):137-45
references.pmid: 9631659
references.citation: Lancet Neurol. 2005 Sep;4(9):543-55
references.pmid: 16109361
references.citation: Curr Opin Neurol. 2006 Oct;19(5):446-50
references.pmid: 16969153
references.citation: J Neurosci. 2010 Nov 3;30(44):14735-44
references.pmid: 21048132
references.citation: Exp Neurol. 2000 Nov;166(1):153-65
references.pmid: 11031091
references.citation: Cell Tissue Res. 2009 Jun;336(3):349-84
references.pmid: 19387688
references.citation: Nat Med. 1996 Jun;2(6):703-7
references.pmid: 8640566